These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain. Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170 [TBL] [Abstract][Full Text] [Related]
4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. Wells JL; Bartlett JL; Ananthan S; Bilsky EJ J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048 [TBL] [Abstract][Full Text] [Related]
6. [Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine. Riba P; Ben Y; Nguyen TM; Furst S; Schiller PW; Lee NM Curr Med Chem; 2002 Jan; 9(1):31-9. PubMed ID: 11860345 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors. Wtorek K; Adamska-Bartłomiejczyk A; Piekielna-Ciesielska J; Ferrari F; Ruzza C; Kluczyk A; Piasecka-Zelga J; Calo' G; Janecka A Molecules; 2019 Dec; 24(24):. PubMed ID: 31817441 [TBL] [Abstract][Full Text] [Related]
8. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain. Podolsky AT; Sandweiss A; Hu J; Bilsky EJ; Cain JP; Kumirov VK; Lee YS; Hruby VJ; Vardanyan RS; Vanderah TW Life Sci; 2013 Dec; 93(25-26):1010-6. PubMed ID: 24084045 [TBL] [Abstract][Full Text] [Related]
9. Spinal administration of the multi-functional opioid/neuropeptide FF agonist BN-9 produced potent antinociception without development of tolerance and opioid-induced hyperalgesia. Zhang R; Xu B; Zhang Q; Chen D; Zhang M; Zhao G; Xu K; Xiao J; Zhu H; Niu J; Li N; Fang Q Eur J Pharmacol; 2020 Aug; 880():173169. PubMed ID: 32416184 [TBL] [Abstract][Full Text] [Related]
11. Analgesic Properties of Opioid/NK1 Multitarget Ligands with Distinct in Vitro Profiles in Naive and Chronic Constriction Injury Mice. Starnowska J; Costante R; Guillemyn K; Popiolek-Barczyk K; Chung NN; Lemieux C; Keresztes A; Van Duppen J; Mollica A; Streicher J; Vanden Broeck J; Schiller PW; Tourwé D; Mika J; Ballet S; Przewlocka B ACS Chem Neurosci; 2017 Oct; 8(10):2315-2324. PubMed ID: 28699350 [TBL] [Abstract][Full Text] [Related]
12. Opioid and substance P receptor adaptations in the rat spinal cord following sub-chronic intrathecal treatment with morphine and naloxone. Gouarderes C; Jhamandas K; Cridland R; Cros J; Quirion R; Zajac JM Neuroscience; 1993 Jun; 54(3):799-807. PubMed ID: 7687333 [TBL] [Abstract][Full Text] [Related]
13. Effect of a selective GABA(B) receptor agonist baclofen on the mu-opioid receptor agonist-induced antinociceptive, emetic and rewarding effects. Suzuki T; Nurrochmad A; Ozaki M; Khotib J; Nakamura A; Imai S; Shibasaki M; Yajima Y; Narita M Neuropharmacology; 2005 Dec; 49(8):1121-31. PubMed ID: 16095635 [TBL] [Abstract][Full Text] [Related]
14. Inhibition by spinal mu- and delta-opioid agonists of afferent-evoked substance P release. Kondo I; Marvizon JC; Song B; Salgado F; Codeluppi S; Hua XY; Yaksh TL J Neurosci; 2005 Apr; 25(14):3651-60. PubMed ID: 15814796 [TBL] [Abstract][Full Text] [Related]
15. Site-Specific Regulation of P2X7 Receptor Function in Microglia Gates Morphine Analgesic Tolerance. Leduc-Pessah H; Weilinger NL; Fan CY; Burma NE; Thompson RJ; Trang T J Neurosci; 2017 Oct; 37(42):10154-10172. PubMed ID: 28924009 [TBL] [Abstract][Full Text] [Related]
16. Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration. Stevenson GW; Giuvelis D; Cormier J; Cone K; Atherton P; Krivitsky R; Warner E; St Laurent B; Dutra J; Bidlack JM; Szabò L; Polt R; Bilsky EJ Psychopharmacology (Berl); 2020 Apr; 237(4):1195-1208. PubMed ID: 31912192 [TBL] [Abstract][Full Text] [Related]
17. Morphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effects. Stone LS; German JP; Kitto KF; Fairbanks CA; Wilcox GL PLoS One; 2014; 9(10):e109903. PubMed ID: 25299457 [TBL] [Abstract][Full Text] [Related]
18. In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice. Lowery JJ; Raymond TJ; Giuvelis D; Bidlack JM; Polt R; Bilsky EJ J Pharmacol Exp Ther; 2011 Mar; 336(3):767-78. PubMed ID: 21118955 [TBL] [Abstract][Full Text] [Related]
19. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300 [TBL] [Abstract][Full Text] [Related]